EZR-ROS1 (~15% of ROS1+ NSCLC) treated identically to other ROS1 fusions. Standard 1L: en...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ROS1-EZR-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ROS1-FUSION |
|---|---|
| Variant | EZR-ROS1 fusion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | repotrectinib monotherapy, entrectinib monotherapy, crizotinib monotherapy |
| Evidence summary | EZR-ROS1 (~15% of ROS1+ NSCLC) treated identically to other ROS1 fusions. Standard 1L: entrectinib, repotrectinib, or crizotinib. |
Notes
ESCAT IA. Partner-agnostic treatment.
Used By
No reverse references found in the YAML corpus.